P90-RSK as a synthetic lethal target in pancreatic cancer - molecular characterization and therapeutic inhibition

Objectives Pancreatic cancer continues to be the cancer entity with the worst prognosis among all solid tumors associated with a 5-year survival of 5-8%. Combined chemotherapeutic regimes provide only survival benefits for a few months and are not equally suited for all patients with advanced pancreatic cancer. Targeted approaches have largely failed. A marginal clinical benefit was seen for an EGFR inhibitior, erlotinib, in combination with chemotherapy. Using a kinome-wide small-interfering RNA (siRNA)-based loss of function screen, we recently identified the kinase RPS6KA2, also known as p90 ribosomal S6 kinase RSK3, as a potential synthetically lethal target in combination with EGFR inhibition.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Jan Riedel, Nada Milosevic, Jens von Kries, Marc Nazare, Heidi Griesmann, Patrick Michl Tags: 4. Experimental pancreatitis and cell biology II Source Type: research